4.68

1.30% +0.06

Tenaya Therapeutics Inc (TNYA)

Overview News Price History Option Chain Financials Discussions Forecast

Tenaya Therapeutics Inc stock is currently priced at $4.68, with a 24-hour trading volume of 89,972. It has seen a +1.30% increased in the last 24 hours and a -2.30% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $4.67 pivot point. If it approaches the $4.75 resistance level, significant changes may occur.

Previous Close:

$4.62

Open:

$4.72

24h Volume:

89,972

Market Cap:

$367.46M

Revenue:

Net Income/Loss:

$-124.08M

P/E Ratio:

-2.0987

EPS:

-2.23

Net Cash Flow:

$-103.31M

1W Performance:

+8.58%

1M Performance:

-2.30%

6M Performance:

+108.00%

1Y Performance:

-20.81%

1D Range:

$4.59

$4.96

52W Range:

$1.66

$8.0914

Tenaya Therapeutics Inc Stock (TNYA) Company Profile

Name

Tenaya Therapeutics Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

760 310 9976

Address

171 Oyster Point Boulevard, Suite 500, South San Francisco

Employee

Twitter

Next Earnings Date

Latest SEC Filings

TNYA's Discussions on Twitter

Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-15-22	Initiated	H.C. Wainwright	Buy

Tenaya Therapeutics Inc Stock (TNYA) Latest News

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

GlobeNewswire Inc.

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire Inc.

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

GlobeNewswire Inc.

Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday

Benzinga

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire Inc.

Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross?

Zacks Investment Research

Tenaya Therapeutics Inc Stock (TNYA) Financials Data

Tenaya Therapeutics Inc (TNYA) Net Income 2024

TNYA net income (TTM) was -$124.08 million for the quarter ending December 31, 2023, a -0.34% decrease year-over-year.

Tenaya Therapeutics Inc (TNYA) Cash Flow 2024

TNYA recorded a free cash flow (TTM) of -$103.31 million for the quarter ending December 31, 2023, a +17.39% increase year-over-year.

Tenaya Therapeutics Inc (TNYA) Earnings per Share 2024

TNYA earnings per share (TTM) was -$1.67 for the quarter ending December 31, 2023, a +40.14% growth year-over-year.

Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.